Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.61 |
| ▸ | HTR3B | O95264 | 2/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.61 |
| ▸ | HTR3A | P46098 | 2/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | CETP | P11597 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylpiperazine SCHEMBL10745401 | 0.92 | SIGMAR1 (0.79) | DRD4SIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL20215708 | 0.87 | HTR1A (0.66) | DRD4SIGMAR1DRD2 | |
| SCHEMBL8145866 | 0.86 | SIGMAR1 (0.96) | DRD4SIGMAR1MEN1ALDH1A1CYP2C9 | |
| SCHEMBL6031812 | 0.86 | DRD4 (1.00) | DRD4SIGMAR1ALDH1A1DRD2DRD3 | |
| SCHEMBL7573306 | 0.86 | SIGMAR1 (0.96) | DRD4SIGMAR1MEN1ALDH1A1CYP2C9 | |
| SCHEMBL9538814 | 0.84 | SIGMAR1 (0.92) | DRD4SIGMAR1MEN1ALDH1A1CYP2C9 | |
| SCHEMBL83548 | 0.84 | SIGMAR1 (1.00) | DRD4SIGMAR1MEN1ALDH1A1CYP2C9 | |
| SCHEMBL6138636 | 0.84 | SIGMAR1 (1.00) | DRD4SIGMAR1MEN1ALDH1A1CYP2C9 | |
| SCHEMBL276363 | 0.84 | SIGMAR1 (1.00) | DRD4SIGMAR1MEN1ALDH1A1CYP2C9 | |
| SCHEMBL152631 | 0.84 | SIGMAR1 (1.00) | DRD4SIGMAR1MEN1ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1057815-B1 | CYCLIC AMIDE COMPOUNDS | KOWA CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-6645957-B2 | Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis | KOWA CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| CN-1114591-C | cyclic amide compound | KOWA CO (JP) | 2003-07-16 | — | — | CN | disclosed |
| US-20030096828-A1 | Cyclic amide compound | KOWA CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-6448242-B1 | COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS | KOWA CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| CN-1291186-A | Cyclic amide compounds | KOWA CO (JP) | 2001-04-11 | — | — | CN | disclosed |
| EP-1057815-A1 | CYCLIC AMIDE COMPOUNDS | Kowa Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096828-A1 | Cyclic amide compound | CMA1, HRH2, HRH4 | DRD4 3954/4885SIGMAR1 1368/4885HTR3E 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.